Accelerating Drug Approvals with Data Standardization: Agenda

The Case for Submission Data Standards
The FDA Perspective on Data Standards
The CDISC Strawman Submission Data Model
The Process for Defining the Strawman Model
Panel Discussion

# The Costs of Chaos: The Case for CDM Standards




Dave Christiansen, Dr PH Principal Biostatistician Genentech, Inc and Wayne R. Kubick Principal PROsys-LLC


04/08/99



### Life Without Standards



- Requires re-orientation and refitting of analysis tools for each submission review
- Encourages variation within the sponsor environment
- Complicates data integration
- Inhibits major software advances





#### Previous Responses to Standards Efforts

- Denial -- Too difficult in our Industry
- Solipsism -- The only good standards are our standards --CANDAs
- Stubbornness -- No one wants to change
- Vendor-phobia -- No one wants to be tied to a vendor
- Regulatory-itis -- Industry resists over-regulation
- Un-Leadership -- Who's willing to go first?
- Low priority -- New Technologies are more interesting than standards.

## **CDISC** Vision

To establish standards to improve the process of electronic acquisition and exchange of clinical trials information

#### The Case for Submission Standards

- FDA Guidelines have set the precedent
- FDA is ready now




- Can dramatically improve review throughput
  - Data pre-organized in familiar patterns means less training and fewer misunderstandings
  - Allows FDA to develop their own analytic tools
- Submission interchange standards are attainable much less complex than a transactional interface
- Gives everyone a common target.

The Strawman Approach to Submission Standards



- Follow the lead of the FDA Guidelines
- Aim for 80% of domains and 80% of variables
- Define basic metadata standards to guide the organization of common datasets
- Begin developing a library for particular therapeutic areas and aim for a superset of submission standards over time
- Support the FDA's efforts to develop standard access, query and analysis tools based on these standards
- Post standards openly and encourage ongoing input and improvement.

## The Strawman Submission Standards Concept



## The FDA Perspective on Submission Data Standards

Current GuidelineFuture Desired Direction

03/08/99



## ESUB Data Strawman Approach

- Organize datasets in folders according to FDA Guidelines
- Define the *Structure* or *Level* of analysis for each dataset
- Classify variables per domain according to *Source*, *Usage* and descriptive *Attributes*
- Link in common *Selection* variables for all datasets
- Use suggested FDA field *Types*, *Codes* and preferred *Labels* wherever possible
- Allow sufficient latitude for adding other variables and domain where scientifically appropriate.


### Taming Chaos: The CDISC "Strawman" MetaData Model




#### Data Model Definitions

- Source Data Information collected and recorded about a subject (Raw data, operational data or primitive data)
- **Derived or Computed Data** Transformation or reduction of one or more data items by a defined process or algorithm
- Analysis Database or Analysis Files A collection of source and derived data items, structured to facilitate data analysis
- Metadata Data about the data; description of the content or purpose of a data base
- Clinical Trial Data Warehouse Analysis files, metadata and documents structured to facilitate the execution and reporting of clinical trials
- Submission Data Mart Subset of a data warehouse specifically designed for submission to a regulatory agency for drug approval

#### Submission Data Mart



## Clinical Directory Structure of an Electronic Submission



Submission Data (and Metadata): Desirable Characteristics

- Should provide clear description of the usage, structure, contents and attributes of all datasets and variables
- Should allow the reviewer to replicate all analyses, tables, graphs and listings with little or no transformation

 Should allow reviewers to easily view and subset the data used to generate any analysis, table, graph or listing Metadata: Description and Contents of the Submission Datasets

- Specified in Guidelines Dataset Name (e.g., DEMO) Description (Demographics) Location (crt/datasets/1234/demo.xpt) Strawman proposes adding <u>Structure</u> or <u>Level</u> • Defines the unit of analysis for a row or observation
  - Useful when multiple datasets are needed for the same clinical domain

## Item Level Lab Dataset: 1 Record/Patient/Visit/Lab Test

Patient	Visit	Test	Value	Status
1234	Base	AAA	95	Low
1234	Base	BBB	122	Normal
1234	1	AAA	89	Low
1234	1	BBB	153	High
1234	4	AAA	91	Low
1234	4	BBB	137	Normal

## Visit Level Lab Dataset: 1 Record/Patient/Visit

Patient	Visit	AAA	BBB
1234	Base	95	122
1234	1	89	153
1234	4	91	137

#### **Dataset Structure Levels**

#### Patient-Level (1 rec/pat)

Demographics, Disposition, Inclusion, Exclusion,

Visit-Level (1 rec/pat/visit)

Visit Type/Date, Vitals, Efficacy Measurements

Incident-Level (1 rec/pat/incident)

AEs, Medications, Diaries, PK, etc.

Item-Level (1 rec/pat/visit/item)

Labs, Medical History, etc.

#### Other (Look-ups, etc.)

Subset Patient Lists, Investigator Lists, Cross-Reference Tables...

#### Metadata: Variable Description

• Specified in Guidelines ◆ Variable Name (e.g., DEMO) ◆ Attributes (Label, Type, Codes...) Comments (Source: CRF, derived...) • Strawman proposes adding Usage ◆ Indicates how the variable is used • Usage may vary by dataset and analysis

#### Data Role Field Classifications

- *K* (Key) Variables -- used to uniquely identify and index each record: Study, Center, Patient ID, Visit, Event Nr
- *S* (Selection) Variables -- frequently used to subset, sort or group data for reporting purposes: Sex, Age, Race, Treatment Group...
- D (Domain) Variables -- variables that relate to the clinical domain and are tabulated and computed for analysis purposes: efficacy measures, lab values, record counts.
- **D** (Descriptive) Variables -- provide other reference information or provide input for deriving variables. Help further identify

## Summary of Strawman Data Model

• Standardize Metadata content and format

- Add Structure to Dataset Description
  - Patient-level
  - Visit-level
  - Incident-level
  - ♦ Item-level

• Add **Role** or Classification to Variable Description

- ♦ Key
- Selection
- Measurement
- ♦ Reference



### **Strawman Definition Process**

- Post first cut Strawman for 8-12 domains on DIA web site -- soon
- Collect comments from industry
- Prepare revised version by June DIA/CDISC meeting
- Phase 1: Complete general metadata model and define primary keys for 8-12 critical domains within 6 months
- Phase 2: Continue developing other domains and identify other areas for increased standardization as an ongoing practice.



## Questions for the Panel

- Will the strawman approach work?
- How do we get FDA and industry input?
- Can we really define one set of data that meets both CRT and statistical analysis requirements?
- Can industry really agree on standards for domains, fieldnames?
- Can this be accomplished without inhibiting science?
- Can this be accomplished in our lifetimes?

#### Questions and Comments?

## Contact: Wayne-kubick@prosys-llc.com davec@gene.com or the CDISC home page: